As a result of the partnership, clinicians using Epic will be able to order Foundation Medicine's genomic profiling tests directly from the EHR and view results in the system, providing them with clinical decision support.
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
The company announced Wednesday the FDA approval of its liquid biopsy test, the second to win an agency nod in less than a month, saying it would launch the product on Friday. The FDA acquired the first ever liquid biopsy companion diagnostic, Guardant Health's Guardant360 CDx, on Aug. 10.
Although they've seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.
The company filed for FDA approval of the FoundationOne Liquid test at the end of December. Data from a clinical trial presented at an October conference showed the test had a strong ability to detect a genetic driver mutation in lung cancer.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In the panel "The Data Problem in Scaling Artificial Intelligence in Healthcare" at the recent MedCity CONVERGE conference, experts from big pharma and health tech discussed challenges in scaling AI such as data gaps and navigating the potential ethical pitfalls of democratizing data.
In a panel discussion at the MedCity CONVERGE conference exploring the opportunities and challenges posed by the data underpinning AI tools, panelists representing big pharma, health tech and clinical data network shared some of their insights.
Data published in JAMA on lung cancer patients treated with immunotherapy drugs, gleaned from EHRs and genomic sequencing, backs up clinical trial data and validates clinico-genomic database, the companies said.
The contract, to provide comprehensive genomic sequencing to VA cancer patients, affords significant opportunities to conduct clinical research, a company executive said.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
With the approval of Loxo's Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.
Merck and Palantir Technologies are forming a joint research venture called Syntropy as a way to offer data analytics tools to healthcare organizations.
Prostate cancer survivor Bryce Olson says genomic sequencing shows the way forward in cancer treatment, rather than the one-size-fits-all approach.
The partnership will also enable Foundation Medicine to move into ex-US markets like Japan, where it is working with drugmaker Chugai.
Chief Commercial Officer Tom Civik said he sees reimbursement of its NGS test as opening the door for liquid biopsy reimbursement as well.